Aevum is pioneering the discovery and development of therapeutic molecules derived from exercised muscle to treat diseases that are known to benefit from exercise. Our lead program is being developed for the treatment of Parkinson’s disease and other related neurodegenerative disorders. Focus/Therapeutic Area: Neuro Stage/Status: Seed Website: —
Aevum Therapeutics Read More »
Crosslink is engineering cancer medicines that conditionally assemble in the tumor microenvironment. Our technology can be adapted to multiple therapeutic modalities, improving safety and efficacy. Focus/Therapeutic Area: Oncology Stage/Status: Seed Website: —
Crosslink Therapeutics Read More »
Kobuk is developing precision biologics to treat autoimmune and inflammatory diseases, focusing on achieving exceptional safety and broad therapeutic reach. Focus/Therapeutic Area: Inflammation and immunology Stage/Status: Seed Website: —
Kobuk Therapeutics Read More »
Permeasis utilizes its proprietary delivery technology to promote the intracellular delivery of a broad range of membrane impermeable cargo proteins. The technology allows the creation of a novel class of therapeutics (“intracellular biologics”) designed to address unmet medical needs outside the reach of traditional small molecules or biologics. Focus/Therapeutic Area: Platform Stage/Status: Seed Website: —
With a novel approach to precision oncology, Tasca Therapeutics is unlocking post-translational modification of proteins by utilizing our state-of-the-art chemical biology and computational approaches, and combining with inhibition at key metabolic nodes to generate drugs for previously considered undruggable targets. Tasca is focused on using its proprietary platform to develop small molecule drugs for hard-to-treat
Tasca Therapeutics Read More »
Tortugas is developing therapeutics for neurological diseases of high unmet need. We focus on translational approaches to allow for rapid identification of efficacy and impact. Focus/Therapeutic Area: Neuro Stage/Status: Seed Website: —
Tortugas Neuroscience Read More »
Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body. Focus/Therapeutic Area: Oncology Stage/Status: Seed Website: https://www.xenimmune.com
